Myelin proteolipid protein (PLP1) (PLP1)

Myelin proteolipid protein (PLP1) is the most abundant protein in the central nervous system (CNS) myelin, comprising approximately 50% of the total protein mass. As a four-transmembrane domain protein, it is essential for the structural integrity, compaction, and long-term maintenance of the myelin sheath that insulates axons. PLP1 exists in two isoforms, PLP and DM20, produced by alternative splicing, and it is crucial for the physical stability of the myelin membrane and the metabolic support of neurons (UniProt P60201; StatPearls). In clinical medicine, PLP1 is a high-profile target due to its involvement in X-linked leukodystrophies. Mutations or duplications of the PLP1 gene cause Pelizaeus-Merzbacher disease (PMD) and Spastic paraplegia type 2 (SPG2), where excessive or misfolded protein leads to oligodendrocyte death and profound neurological deficits (NIH/NINDS). Furthermore, PLP1 is a primary autoantigen in the autoimmune pathogenesis of Multiple Sclerosis (MS). Modern therapeutic strategies are shifting toward genetic modulation, specifically using antisense oligonucleotides (ASOs) to normalize PLP1 levels in duplication cases or gene therapies to restore function (Nature, 2020; PubMed).

Other names

Proteolipid protein 1PLPDM20LipophilinMyelin proteolipid protein 1PMLD

Reduction of toxic protein accumulation via antisense-mediated knockdown; induction of immune tolerance through peptide vaccines; gene replacement or correction in deficiency states.